Full Press Release Details
MediciNova Initiates a Second Phase I Clinical Trial
with MN-029 in Cancer Patients
Novel Vascular Targeting
Agent Well Tolerated in Earlier Trial
SAN DIEGO, Calif. June 17,
2005 MediciNova, Inc., a specialty pharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange (Code number: 4875), today announced the initiation of a second Phase I study with MN-029 in patients
with solid tumors. MN-029 is a vascular targeting agent (VTA) that in preclinical studies demonstrated greater potency with possibly less cardiovascular and central nervous system toxicity than first generation VTAs. In September of 2004, the
Company initiated a Phase I clinical trial in patients with solid tumors. That study is nearing completion.
MN-029 has been well tolerated at each dosing level throughout the current Phase I clinical study, and we are planning in this second study to implement a more aggressive, yet simpler dosing schedule that will
be compatible with a wide range of cancer treatment regimens, stated Richard E. Gammans, Ph.D., Chief Development Officer at MediciNova.
MediciNova has exclusive worldwide rights to MN-029, which was acquired from Angiogene Pharmaceuticals of Oxford, U.K., in 2002.
MediciNova, Inc. is a publicly traded specialty pharmaceutical company focused on accelerating the global development and commercialization of innovative pharmaceutical
products. MediciNova s pipeline, which includes several compounds in clinical testing, targets a variety of prevalent medical conditions, including premature labor, cancer, asthma, multiple sclerosis and anxiety disorders. For more information
on MediciNova Inc., please visit www.medicinova.com.
This press release may
contain forward looking statements as defined by the Securities and Exchange Commission. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that the
Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made by the Company based on management s experience and perception of historical trends,
current conditions, expected future developments and other factors it believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the
Company, which may cause the Company s actual results to differ materially from those implied or expressed by the forward-looking statements. These risks include the risk factors detailed in MediciNova s Securities and Exchange Commission